US5767240A
(en)
*
|
1991-04-22 |
1998-06-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Activity-dependent neurotrophic factor
|
US6174862B1
(en)
*
|
1991-04-22 |
2001-01-16 |
Ramot University Authority For Applied Research And Industrial Development, Ltd. |
Neurotrophic peptides of activity dependent neurotrophic factor
|
DK0700445T3
(da)
*
|
1993-06-04 |
2002-05-13 |
Whitehead Biomedical Inst |
Stressproteiner og anvendelser deraf
|
US5997873A
(en)
|
1994-01-13 |
1999-12-07 |
Mount Sinai School Of Medicine Of The City University Of New York |
Method of preparation of heat shock protein 70-peptide complexes
|
US5750119A
(en)
*
|
1994-01-13 |
1998-05-12 |
Mount Sinai School Of Medicine Of The City University Of New York |
Immunotherapeutic stress protein-peptide complexes against cancer
|
US5961979A
(en)
|
1994-03-16 |
1999-10-05 |
Mount Sinai School Of Medicine Of The City University Of New York |
Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
|
IL109790A0
(en)
*
|
1994-05-25 |
1994-08-26 |
Yeda Res & Dev |
Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
|
US5738855A
(en)
*
|
1994-10-17 |
1998-04-14 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide
|
AU727673B2
(en)
*
|
1995-09-13 |
2000-12-21 |
Fordham University |
Therapeutic and prophylactic methods using heat shock proteins
|
US5935576A
(en)
|
1995-09-13 |
1999-08-10 |
Fordham University |
Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
|
US5985270A
(en)
*
|
1995-09-13 |
1999-11-16 |
Fordham University |
Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
|
US5837251A
(en)
*
|
1995-09-13 |
1998-11-17 |
Fordham University |
Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
|
ES2258796T3
(es)
*
|
1996-11-26 |
2006-09-01 |
Stressgen Biotechnologies Corporation |
Proteinas de fusion que contienen proteinas de estres para inducir respuestas inmunitarias.
|
US7157089B1
(en)
|
1996-11-26 |
2007-01-02 |
Stressgen Biotechnologies Corporation |
Immune responses using compositions containing stress proteins
|
US5830464A
(en)
|
1997-02-07 |
1998-11-03 |
Fordham University |
Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
|
US6017540A
(en)
|
1997-02-07 |
2000-01-25 |
Fordham University |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
|
WO1998035705A1
(en)
*
|
1997-02-18 |
1998-08-20 |
Whitehead Institute For Biomedical Research |
Use of heat shock proteins to deliver moieties into cells
|
ES2266652T3
(es)
|
1997-08-05 |
2007-03-01 |
Stressgen Biotechnologies Corporation |
Respuestas inmunologicas contra los antigenos de hpv provocadas por compuestos que contienen un antigeno de hpv y una proteina de stress o un vector de expresion capaz de expresar dichas proteinas.
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US5948646A
(en)
|
1997-12-11 |
1999-09-07 |
Fordham University |
Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
|
ATE359084T1
(de)
|
1998-02-20 |
2007-05-15 |
Univ Miami |
Modifizierter hitzeschockprotein/peptidantigen komplex
|
DE19821859A1
(de)
*
|
1998-05-15 |
1999-12-09 |
M Alexander Schmidt |
Darstellung immunogener (Kapsel-)Polysaccharid-Konjugate durch orientierte Kupplung synthetischer T-Zell-Epitope zur Erzeugung von Vakzinen gegen N.meningitidis
|
KR20020013470A
(ko)
*
|
1998-10-02 |
2002-02-20 |
미우라 아키라 |
세포성 면역의 유도방법 및 세포성 면역이 유도된 세포
|
US6497880B1
(en)
|
1998-12-08 |
2002-12-24 |
Stressgen Biotechnologies Corporation |
Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
|
CA2378097A1
(en)
|
1999-07-08 |
2001-01-18 |
Stressgen Biotechnologies Corporation |
Induction of a th1-like response in vitro
|
CN1108820C
(zh)
*
|
1999-11-12 |
2003-05-21 |
清华大学 |
单表位重复或多联单表位重复-表位疫苗的制备方法
|
CA2396384A1
(en)
|
2000-01-14 |
2001-07-19 |
Whitehead Institute For Biomedical Research |
In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
|
AU2001266694C1
(en)
|
2000-06-02 |
2005-09-01 |
University Of Connecticut Health Center |
Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
|
EE200200709A
(et)
|
2000-06-26 |
2004-08-16 |
Stressgen Biotechnologies Corporation |
Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
|
US7082569B2
(en)
|
2001-01-17 |
2006-07-25 |
Outlooksoft Corporation |
Systems and methods providing dynamic spreadsheet functionality
|
JP2005505238A
(ja)
|
2001-02-05 |
2005-02-24 |
ストレスゲン バイオテクノロジーズ コーポレイション |
B型肝炎ウイルスの治療法
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
CA2457008A1
(en)
|
2001-08-20 |
2003-02-27 |
University Of Connecticut Health Center |
Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease
|
ES2526822T3
(es)
*
|
2002-01-31 |
2015-01-15 |
Andromeda Bio Tech Ltd. |
Péptidos hsp y análogos para la modulación de respuestas inmunes mediante células presentadoras de antígeno
|
AU2003209623A1
(en)
*
|
2002-02-19 |
2003-09-09 |
Yeda Research And Development Co. Ltd. |
Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
MXPA04011249A
(es)
|
2002-05-14 |
2005-06-06 |
Chiron Srl |
Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
DE60335477D1
(de)
|
2002-10-11 |
2011-02-03 |
Novartis Vaccines & Diagnostic |
Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
|
AU2003288660A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
EP2172213B1
(de)
|
2003-01-30 |
2013-04-03 |
Novartis AG |
Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
|
PL1961426T3
(pl)
|
2003-10-02 |
2012-03-30 |
Gsk Vaccines S R L |
Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0408978D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Meningococcal fermentation for preparing conjugate vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
CA2575548A1
(en)
|
2004-07-29 |
2006-07-27 |
John L. Telford |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
JP2008523815A
(ja)
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
認知の改善における使用のためのヒト化アミロイドβ抗体
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
ES2385045T3
(es)
|
2005-02-18 |
2012-07-17 |
Novartis Vaccines And Diagnostics, Inc. |
Inmunógenos de Escherichia coli uropatogénica
|
SI2351772T1
(sl)
|
2005-02-18 |
2016-11-30 |
Glaxosmithkline Biologicals Sa |
Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
|
JP2008536515A
(ja)
|
2005-04-18 |
2008-09-11 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
ワクチンの調製のためのb型肝炎ウイルス表面抗原の発現
|
KR20130122810A
(ko)
|
2005-06-27 |
2013-11-08 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신 제조 방법
|
EP1931380A2
(de)
|
2005-09-01 |
2008-06-18 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Multiple impfung mit serogruppen c meningococcus
|
GB0522303D0
(en)
|
2005-11-01 |
2005-12-07 |
Chiron Srl |
Culture method
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
ES2514316T3
(es)
|
2005-11-22 |
2014-10-28 |
Novartis Vaccines And Diagnostics, Inc. |
Partículas similares a virus (VLPs) de Norovirus y Sapovirus
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
EP3020411A1
(de)
|
2005-12-22 |
2016-05-18 |
GlaxoSmithKline Biologicals s.a. |
Impfstoff
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
ES2670231T3
(es)
|
2006-03-22 |
2018-05-29 |
Glaxosmithkline Biologicals S.A. |
Regímenes para inmunización con conjugados meningocócicos
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
US8414899B2
(en)
*
|
2006-04-11 |
2013-04-09 |
Yeda Research And Development Co. Ltd. |
Vaccines comprising multimeric HSP60 peptide carriers
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
GB0612854D0
(en)
|
2006-06-28 |
2006-08-09 |
Novartis Ag |
Saccharide analysis
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
PL2066344T3
(pl)
|
2006-09-07 |
2011-10-31 |
Glaxosmithkline Biologicals Sa |
Skojarzona szczepionka zawierająca inaktywowany wirus polio
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
BRPI0810778A2
(pt)
|
2007-05-02 |
2011-09-13 |
Glaxosmithkline Biolog Sa |
kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
|
WO2009000825A2
(en)
|
2007-06-26 |
2008-12-31 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
EP2182983B1
(de)
|
2007-07-27 |
2014-05-21 |
Janssen Alzheimer Immunotherapy |
Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
BRPI0816689B1
(pt)
|
2007-09-12 |
2021-08-24 |
Novartis Ag |
Composição de vacina, kit e método para a confecção de uma composição de vacina para a prevenção ou tratamento de infecção por streptococcus pyogenes
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
EP2200642B1
(de)
|
2007-10-19 |
2012-04-18 |
Novartis AG |
Meningokokkenimpfstoffformulierungen
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CA2709927C
(en)
|
2007-12-21 |
2017-05-16 |
Novartis Ag |
Mutant forms of streptolysin o
|
AU2009215364B2
(en)
|
2008-02-21 |
2014-09-18 |
Glaxosmithkline Biologicals S.A. |
Meningococcal fHBP polypeptides
|
EP2752193B1
(de)
|
2008-03-03 |
2017-01-11 |
The University of Miami |
Auf allogenen Krebszellen basierende Immunotherapie
|
CN102036677A
(zh)
|
2008-03-20 |
2011-04-27 |
迈阿密大学 |
热休克蛋白gp96的疫苗接种及其使用方法
|
GB0810894D0
(en)
|
2008-06-13 |
2008-07-23 |
Novartis Vaccines & Diagnostic |
Conjugated saccharide
|
JP5689064B2
(ja)
|
2008-10-27 |
2015-03-25 |
ノバルティス アーゲー |
精製方法
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
EP2367568A2
(de)
|
2008-12-17 |
2011-09-28 |
Novartis AG |
Meningokokken-impfstoffe mit hämoglobin-rezeptor
|
EP2385842A1
(de)
|
2009-01-12 |
2011-11-16 |
Novartis AG |
Cna_b-domänen-antigene in impfstoffen gegen grampositive bakterien
|
WO2010109324A1
(en)
|
2009-03-24 |
2010-09-30 |
Novartis Ag |
Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
|
CA2756522C
(en)
|
2009-03-24 |
2018-06-26 |
Novartis Ag |
Adjuvanting meningococcal factor h binding protein
|
CN109248313B
(zh)
|
2009-04-14 |
2023-01-17 |
葛兰素史密丝克莱恩生物有限公司 |
用于免疫接种以抵御金黄色葡萄球菌的组合物
|
WO2010125480A1
(en)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
AU2010288240B2
(en)
|
2009-08-27 |
2014-03-27 |
Novartis Ag |
Hybrid polypeptides including meningococcal fHBP sequences
|
MY163512A
(en)
|
2009-09-03 |
2017-09-15 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
EP2475385A1
(de)
|
2009-09-10 |
2012-07-18 |
Novartis AG |
Kombinationsimpfstoffe gegen atemwegserkrankungen
|
BR112012009014B8
(pt)
|
2009-09-30 |
2022-10-04 |
Novartis Ag |
Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
JP5960055B2
(ja)
|
2009-10-27 |
2016-08-02 |
ノバルティス アーゲー |
改変髄膜炎菌fHBPポリペプチド
|
RS56000B1
(sr)
|
2009-10-30 |
2017-09-29 |
Glaxosmithkline Biologicals Sa |
Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
AU2011268507B2
(en)
|
2010-06-25 |
2014-08-14 |
Novartis Ag |
Combinations of meningococcal factor H binding proteins
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
US10286056B2
(en)
|
2011-01-27 |
2019-05-14 |
Glaxosmithkline Biologicals S.A. |
Adjuvant nanoemulsions with crystallisation inhibitors
|
JP6191082B2
(ja)
|
2011-03-02 |
2017-09-06 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
より低用量の抗原および/またはアジュバントを有する混合ワクチン
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
EP2688590B1
(de)
|
2011-03-24 |
2020-02-12 |
GlaxoSmithKline Biologicals SA |
Adjuvante nanoemulsionen mit phospholipiden
|
JP6088507B2
(ja)
|
2011-07-08 |
2017-03-01 |
ノバルティス アーゲー |
チロシンライゲーションの方法
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2013038375A2
(en)
|
2011-09-14 |
2013-03-21 |
Novartis Ag |
Methods for making saccharide-protein glycoconjugates
|
WO2013068949A1
(en)
|
2011-11-07 |
2013-05-16 |
Novartis Ag |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
EP2592137A1
(de)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Fermentierungsmedium ohne Bestandteile tierischen Ursprungs zur Herstellung von Diphtherie-Impfstoffen zur menschlichen Impfung
|
ES2704069T3
(es)
|
2011-12-08 |
2019-03-14 |
Glaxosmithkline Biologicals Sa |
Vacuna basada en toxinas de Clostridium difficile
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
EP2797624A1
(de)
|
2011-12-29 |
2014-11-05 |
Novartis AG |
Kombinationen aus meningokokken-faktor-h-bindenden proteinen
|
CN104321335A
(zh)
|
2012-02-24 |
2015-01-28 |
诺华股份有限公司 |
菌毛蛋白质和组合物
|
US20150132339A1
(en)
|
2012-03-07 |
2015-05-14 |
Novartis Ag |
Adjuvanted formulations of streptococcus pneumoniae antigens
|
US20150125486A1
(en)
|
2012-03-08 |
2015-05-07 |
Novartis Ag |
Adjuvanted formulations of pediatric antigens
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
RU2727476C2
(ru)
|
2012-04-26 |
2020-07-21 |
Новартис Аг |
Антигены и антигенные композиции
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
US10124051B2
(en)
|
2012-05-22 |
2018-11-13 |
Glaxosmithkline Biologicals Sa |
Meningococcus serogroup X conjugate
|
AU2013311702A1
(en)
|
2012-09-06 |
2015-02-19 |
Novartis Ag |
Combination vaccines with serogroup B meningococcus and D/T/P
|
ES2848048T3
(es)
|
2012-10-03 |
2021-08-05 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas
|
SG11201502599TA
(en)
|
2012-10-12 |
2015-05-28 |
Glaxosmithkline Biolog Sa |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
CN105188747A
(zh)
|
2013-02-01 |
2015-12-23 |
葛兰素史密斯克莱生物公司 |
包含toll样受体激动剂的免疫组合物的皮内递送
|
EP2870974A1
(de)
*
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella-Konjugatimpfstoffe
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
HUE055553T2
(hu)
|
2014-01-21 |
2021-12-28 |
Pfizer |
Streptococcus pneumoniae kapszulás poliszacharidok és azok konjugátumai
|
IL296681B2
(en)
|
2014-01-21 |
2024-09-01 |
Pfizer |
Immunogenic preparations including conjugated capsular saccharide antigens and their uses
|
EP3957321A3
(de)
|
2014-01-21 |
2022-07-13 |
Pfizer Inc. |
Kapsulare polysaccharide aus streptococcus pneumoniae und konjugate davon
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CA2939416A1
(en)
|
2014-02-14 |
2015-08-20 |
Pfizer Inc. |
Immunogenic glycoprotein conjugates
|
CA2940447C
(en)
|
2014-02-28 |
2023-07-11 |
Glaxosmithkline Biologicals Sa |
Modified meningococcal fhbp polypeptides
|
EP3034516A1
(de)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Reinigung von Streptokokkenkapselpolysaccharid
|
CN107427568B
(zh)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
SG11201705844SA
(en)
|
2015-02-06 |
2017-08-30 |
Heat Biologics Inc |
Vector co-expressing vaccine and costimulatory molecules
|
PE20240927A1
(es)
|
2015-07-21 |
2024-04-30 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
US10993971B2
(en)
|
2015-12-04 |
2021-05-04 |
Dana-Farber Cancer Institute, Inc. |
Vaccination with MICA/B alpha 3 domain for the treatment of cancer
|
US11612664B2
(en)
|
2016-04-05 |
2023-03-28 |
Gsk Vaccines S.R.L. |
Immunogenic compositions
|
US20180064801A1
(en)
|
2016-09-02 |
2018-03-08 |
Glaxosmithkline Biologicals Sa |
Vaccines for neisseria gonorrhoeae
|
WO2018071405A1
(en)
|
2016-10-11 |
2018-04-19 |
University Of Miami |
Vectors and vaccine cells for immunity against zika virus
|
BE1025162B9
(fr)
|
2016-12-06 |
2019-01-07 |
Glaxosmithkline Biologicals Sa |
Procede de purification pour les polysaccharides capsulaires
|
PL3570879T3
(pl)
|
2017-01-20 |
2022-06-20 |
Pfizer Inc. |
Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom
|
KR102650073B1
(ko)
|
2017-01-31 |
2024-03-20 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
|
AU2018215585B2
(en)
|
2017-01-31 |
2022-03-17 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
WO2018187260A1
(en)
|
2017-04-04 |
2018-10-11 |
Heat Biologics, Inc. |
Intratumoral vaccination
|
FI3678654T3
(fi)
|
2017-09-07 |
2024-09-02 |
Merck Sharp & Dohme Llc |
Pneumokokkipolysakkaridit ja niiden käyttö immunogeenisissä polysakkaridi-kantajaproteiini-konjugaateissa
|
CN117982633A
(zh)
|
2017-12-06 |
2024-05-07 |
默沙东有限责任公司 |
包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
|
BR112021000529A2
(pt)
|
2018-07-19 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Processos para preparar polissacarídeos secos
|
EP3607967A1
(de)
|
2018-08-09 |
2020-02-12 |
GlaxoSmithKline Biologicals S.A. |
Modifizierte meningokokken fhbp polypeptide
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
SG11202106541WA
(en)
|
2018-12-19 |
2021-07-29 |
Merck Sharp & Dohme |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
US20220118072A1
(en)
|
2019-02-11 |
2022-04-21 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
CN113966234A
(zh)
|
2019-05-10 |
2022-01-21 |
葛兰素史克生物有限公司 |
缀合物的产生
|
EP4003410A1
(de)
|
2019-07-31 |
2022-06-01 |
Sanofi Pasteur, Inc. |
Multivalente pneumokokken-polysaccharid-protein-konjugat-zusammensetzungen und verfahren zu ihrer verwendung
|
CN115605222A
(zh)
|
2019-09-27 |
2023-01-13 |
辉瑞公司(Us) |
脑膜炎奈瑟氏菌组合物及其方法
|
WO2021084429A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CN114728051A
(zh)
|
2019-11-22 |
2022-07-08 |
葛兰素史克生物有限公司 |
细菌糖糖缀合物疫苗的剂量和施用
|
BR112022015796A2
(pt)
|
2020-02-21 |
2022-10-11 |
Pfizer |
Purificação de sacarídeos
|
WO2021165928A2
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2021250626A2
(en)
|
2020-06-12 |
2021-12-16 |
Glaxosmithkline Biologicals Sa |
Dock tag system
|
GB202013262D0
(en)
|
2020-08-25 |
2020-10-07 |
Glaxosmithkline Biologicals Sa |
Vaccine Composition
|
EP4232593A1
(de)
|
2020-10-22 |
2023-08-30 |
Pfizer Inc. |
Verfahren zur reinigung von bakteriellen polysacchariden
|
AU2021368151B2
(en)
|
2020-10-27 |
2024-09-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20240000912A1
(en)
|
2020-11-04 |
2024-01-04 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
EP4333879A1
(de)
|
2021-05-03 |
2024-03-13 |
Pfizer Inc. |
Impfung gegen bakterielle und betacoronavirus-infektionen
|
WO2022249107A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP4346892A2
(de)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
|
IL314243A
(en)
|
2022-01-13 |
2024-09-01 |
Pfizer |
Immunogenic preparations containing conjugates of capsular sugar antigen and their uses
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
GB202208089D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
GB202208093D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|